|Ms. Jeane Mike Tsutsui||CEO & Member of Exec. Board||N/A||N/A||N/A|
|Mr. Jose Antonio de Almeida Filippo||Exec. Director of Fin., Investor Relations and Legal & Member of Exec. Board||N/A||N/A||1960|
|Mr. Claudio Almeida Prado||Exec. Director of New Links & Member of Exec. Board||N/A||N/A||N/A|
|Mr. Edgar Gil Rizzatti||Medical, Technical & Process Exec. Director and Member of Exec. Board||N/A||N/A||N/A|
|Rodrigo Manso||Investor Relations Sr. Mang.||N/A||N/A||N/A|
|Mr. Fernando Aguiar Camargo||Sec.||N/A||N/A||N/A|
|Mr. Luís Mário Bilenky||Exec. Officer of Commercial and Marketing||N/A||N/A||N/A|
Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and image exam, diagnostic information, check-up and reference laboratory, genomics, clinic day, center of infusions, dental imaging exam, dental radiology, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including teleconsultations, medical, diagnostic medicine exams, and procedures; and corporate solutions and face-to-face primary care, as well as solutions for physicians with digital office and medical education. It operates 284 customer service units and 31 hospital-based units under the Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, a+ and Diagmax, a+, IRN / CPC, Diagnosis a+, a+BA, and Pretti and Bioclinic brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.
Fleury S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.